Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
2 hedge funds and large institutions have $78.3K invested in Y-mAbs Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 95 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
61.57% less ownership
Funds ownership: 61.61% → 0.04% (-62%)
98% less funds holding
Funds holding: 97 → 2 (-95)
100% less capital invested
Capital invested by funds: $126M → $78.3K (-$126M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIG
Brooklyn Investment Group
Brooklyn,
New York
|
+$74.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$19.1M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
-$15.4M |
| 3 |
BlackRock
New York
|
-$12.4M |
| 4 |
CP
Caligan Partners
New York
|
-$10.6M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$9.9M |
YMAB Hedge Fund Activity: Q3 2025 in Review
2 of the 7,642 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2025, worth a combined $78.3K — down 100% from $126M a quarter earlier.
Sellers outnumbered buyers: 95 funds closed out of YMAB and 0 opened new positions — a net loss of 95 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Brooklyn Investment Group, adding an estimated $74.4K. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $19.1M sold.
- 2 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2025, down from 97 in Q2 2025.
- Funds reported $78.3K of Y-mAbs Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Y-mAbs Therapeutics positions in Q3 2025 and 95 closed out, a net change of -95 holders.
- The largest Y-mAbs Therapeutics buyer in Q3 2025 was Brooklyn Investment Group, an estimated $74.4K added.
- The largest Y-mAbs Therapeutics seller in Q3 2025 was Paradigm Biocapital Advisors, an estimated $19.1M sold.
Based on aggregated 13F filings for Q3 2025.